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In this studywe examined potential limitations ofrelyingexcdusively on blood lead (BPb) levels
to evaluate children with moderatdy elevated BPb levels (1.21-2.12 pmol/l, or 25-44 pg/dl).
We tested the following hypotheses: 1) such children without elevated erythrocyte protopor-
phyrin (EP) levels (.0.62 pmol/l or.35 pg/dl) are unlikely to respond to achelating agentwith
a briskurinary Pb diuresis; 2) thosewith elevated EP levels, but low hetolgc indices consis-
tentwith iron deficiency, are alo.unlkly to respondto a chelating agent with a robust urinary
Pb diuresis; and 3) dte with elevated EP levels and iron enyare more likely to respond
to a celatingagent. To test these hypotheses, we perormed retrospective analyses ofthe rMa-
tionships between EP concentrations, hematologic indices, and urinary Pb excretion ratios
(Pbr) i moderatel Pb-poisoned children undergoi the CaNa2EDTA lead mobizaion test
(Pb-MD). Data from 122 children were available. Urinary Pb excretion was limited in children
with an EP <0.62 pmol/l (<35 pgldl); only 5% (1/21) ofPb-MTs were positive (uPbr 20.6). In
children with an EP .0.62 pmolIl, lowhematologicindices, such as a mean corpuscular hemo-
globin (MCH) <23 pg, were associated with relatively litde Pb excreton (0114 positive Pb-
MTs). In contrast, 32% (28/87) ofPb-MTs were positive in children with an EP .0.62 pmol/l
and iron su (pcO.1 by chi-square comparison between groups with EP .0.62 pmol/l
andeither MCH.<23 pgorMCH .:23pg). We conclude thatonlyaminorityofmoderatelyPb-
poisonedchildrenwilldemonste enhan urinaryPb xcretion inresponseto chelation ther-
apy. Some ofthe predicted no nders can be readily ideAtified byadding the EP and com-
plete blood count to the pand oftests performed. Kqy word blood lead levels, chelation, ery-
dthoce pmtoporphyrin, iron defieny, lead diagnosis, lead mobilization test, lead poisoning,
urine lead.
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The management ofchildhood lead poison-
ing has undergone considerable change
since 1991 when the definition of Pb poi-
soning was lowered to a blood Pb (BPb)
level .0.48 pmol/l (10 pg/dl). Universal
screening ofpreschool children was recom-
mended by both the Centers for Disease
Control and Prevention and the American
Academy ofPediatrics, while local epidemi-
ologic data on the prevalence of lead poi-
soning accumulated (1,2).
Historically, erythrocyte protoporphyrin
(EP) measurements were used for Pb screen-
ing purposes (3). This heme precursor accu-
mulates in red (and other) cells in the pres-
ence of Pb or in the absence of sufficient
iron (4). Increases in EP levels .0.62 pmol/l
(.35 pg/dl) are associated with elevated BPb
levels, especially when BPb levels are .2.41
pmol/l (50 pg/dl); reportedly, only about
20% of children with BPb levels between
0.97 and 1.40 pmol/l (20-29 pg/dl) will
have an EP .0.62 pmol/l (.35 pg/dl) (5).
The presence of an elevated EP level thus
indicates the need for BPb and iron status
determinations. However, because EP mea-
surements fail to detect the majority ofchil-
dren with BPb values .0.48 pmol/l (10
pg/dl), the direct measurement of a BPb
level has become the screening method of
choice for childhood Pb poisoning (6).
Chelation therapy employs chemical
agents to remove Pb from critical organs,
thereby ameliorating further toxicity and
potentially allowing for biochemical and
general medical recovery. Their use is rec-
ommended for children with BPb levels
.2.17 pmol/l (45 pg/dl) (1). For children
with BPb levels 0.48-1.16 pmol/l (10-24
pg/dl), chelation therapy is not recommend
except in clinical research protocols (1).
The indication for chelation therapy in
moderately Pb-poisoned children (BPb
1.21-2.12 pmol/l or 25-44 pg/dl) has not
been clearly defined. Approaches to such
children have included nonselective chela-
tion ofall of them on the presumption of
benefit, no chelation for any because ofthe
absence of demonstrated long-term bene-
fit, or selection for chelation based on fur-
ther diagnostic testing. Nonspecific crite-
ria, such as persistence ofelevated BPb lev-
els despite environmental intervention,
have also been offered as justifications for
this form of treatment, but without sup-
porting evidence (7).
One diagnostic test that has been used
in past decades for moderately Pb-poisoned
children is the CaNa2EDTA lead mobiliza-
tion test (Pb-MT). This test examines the
immediate responsiveness of the patient to
a chelating agent, CaNa2EDTA, in terms
of urinary Pb excretion. Its historical devel-
opment was predicated on the observation
that workers in lead-based industries excret-
ed larger amounts of Pb in response to this
drug than nonexposed workers, despite
comparable BPb levels; this responsiveness
appeared to be related to the duration of
exposure (8). The Pb-MT highlighted the
limitations of relying solely on BPb level
determinations as the predictor of the
amount ofPb in other body compartments.
The later development ofbone Pb measure-
ments by L-X-ray fluorescence in diverse
populations confirmed this limitation of
BPb (8). The Pb-MT was later adapted for
children (9). A significant or positive Pb-
MT was defined, in part, by a level of
induced Pb excretion greater than the
amount the child could or would excrete
spontaneously. Because chelation-induced
urinary lead excretion is comparable for the
first 5 days of treatment, a positive Pb-MT
is a predictor of responsiveness, in terms of
Pb excretion, to a full 5-day course oftreat-
mentwith the same drug (10).
Practical and theoretical considerations,
however, have limited the utility, availabili-
ty, and possible advisability of the Pb-MT.
In particular, it requires parenteral adminis-
tration of a drug and a timed urine collec-
tion ofat least 6 and preferably 8 hr (11,12).
An unreplicated study found transient, but
not sustained, elevations in brain Pb content
after single dose injections of CaNa2EDTA
given to leaded rats (13). No clinical corre-
lates to this study have been described in
humans. Finally, whether children chelated
on the basis ofthis test have better outcomes
has also not been examined.
Thus, the BPb level has become the sole
biochemical determinant for clinical man-
agement. In this study we have examined
potential limitations ofrelying exclusively on
BPb levels to determine the need for chela-
tion therapy in children with moderately ele-
vated BPb levels. In particular, we explored
the heterogeneity in the population of chil-
dren defined by comparable BPb levels. We
attempted to define subgroups ofsuch chil-
dren by combining measures ofPb exposure
(BPb), toxicity (EP), and drug responsive-
ness (Pb-MT). We tested the following
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hypotheses: 1) children with moderately ele-
vated BPb levels but low EP levels (<0.62
pmol/1 or <35 pg/dl) are unlikely to have a
Pb diuresis in response to CaNa2EDTA; 2)
a subset of patients with elevated BPb and
EP levels, the latter measure high as the
result ofiron deficiency rather than Pb poi-
soning, will not respond to this chelating
agentwith a urinary Pb diuresis; and 3) chil-
dren with elevated BPb and EP levels, but
without evidence of iron deficiency, are
more likely to have accumulated Pb stores
and are more likely to respond to achelating
agent with a Pb diuresis.
Methods
We performed a retrospective analysis of
data obtained from children who complet-
ed Pb-MTs over an 18-month period
(March 1992-October 1993). The chil-
dren were referred to our lead clinic in the
Bronx, New York, for the evaluation of a
screening BPb level of 1.21-2.12 pmol/l.
Case selection began after BPb replaced EP
as the recommended screening method to
detect childhood Pb poisoning (1).
Nonetheless, our laboratory continued to
measure EP levels in children who had BPb
values .1.21 pmol/l. The children were
between 1 and 6 years ofage.
The Pb-MT protocol we used was as
follows. We began by obtaining a blood
sample for later BPb and EP determinations
on the day of the test. A single dose of
CaNa2EDTA (500 mg/M2), mixed 1:1 by
volume with 1% procaine, was adminis-
tered in the quadriceps (alternatively, the
drug without procaine can be given intra-
venously). This marked the beginning ofan
8-hr urine collection period for later Pb
determination (9,11). Urine Pb content
(uPb; in micrograms) was divided by the
dose ofCaNa2EDTA given (in milligrams)
to yield the uPb/CaNa2EDTA ratio (uPbr).
A ratio .0.6 is considered a significant Pb
diuresis (a positive test) and indicates the
need for further chelation therapy (14).
As indirect measures ofiron sufficiency, a
blood sample for complete blood count
(CBC) analysis was also obtained within 1
month prior to the Pb-MT. Measures on the
CBC were the hematocrit (Hct), hemoglobin
(Hgb), mean corpuscular volume (MCV),
and mean corpuscularhemoglobin (MCH).
Blood and urine Pb were measured by
graphite furnace atomic absorption spec-
trometry; the 95% confidence limits ofthe
methods are 0.048 pmol/l (1 pg/dl) and
0.241 pmol/volume (5 pg/volume), respec-
tively (10). EP was measured by the ethyl-
acetate-acetic acid extraction method (4).
The CBC was measured on an automated
instrument (Cell-Dyn 900, Sequoia
Turner).
Data analyses included inspection ofthe
data to determine cutoffs of predictors of
the Pb-MT. Statistical techniques included
chi-square and regression analyses, with
uPbr as the dependent variable. For the
regression analyses, a stepwise approach was
used. Because ofsignificant skew and kurto-
sis in its distribution, the log of EP was
used in the statistical analyses.
Results
Complete data from 122 children were avail-
able for analyses. Ninety percent.of the chil-
dren were Hispanic or African American;
85% received Medicaid orwere self-paying.
Only mean uPbr and the percentage of
positive Pb-MTs (uPbr .0.6) were signifi-
cantly different between the high and low
EP groups (Table 1). Inspection ofthe dis-
tributions of uPbr versus BPb or age did
not provide clinically useful information,
i.e., cutoffs predictive ofa negative Pb-MT.
The distribution ofuPbr results by levels of
EP, MCH, MCV, Hgb, and, to a lesser
extent, Hct are noteworthy, as shown for
EP and MCH in Figure 1 (similar plots for
uPbr versus MCV, Hgb, and Hct are avail-
able on request). Twenty-one of the 122
children (17.2%) had EP levels <0.62
pmol/l (<35 pg/dl) on the day of testing
(Table 2). Of these, only one had a uPbr
.0.6 (4.8%) (Fig. 1, Table 2). In contrast,
28 of the 101 Pb-MTs performed in chil-
dren with elevated EP levels were positive
(27.7%). The difference in the proportion
ofpositive and negative Pb-MTs (i.e., uPbr
.0.6 and <0.6, respectively) in the two EP
groups (EP .0.62 pmol/l and <0.62
pmol/l, respectively) was significant by chi-
square analysis (p<0.05).
The distribution of Pb-MT results by
MCH is also shown in Figure 1. Inspection
ofthese data revealed a distinct group char-
acterized by an MCH <23 pg; no members
ofthis group had a positive Pb-MT (0/18).
In contrast, 29 of 104 Pb-MTs performed
in children with an MCH .23 pg were
positive (27.9%;p<0.05).
When the uPbr data are grouped by EP
and MCH (Table 2), it is evident that low
values ofeither alone is predictive ofa nega-
tive Pb-MT. Only ifboth EP and MCH are
elevated does uPbr become unpredictable.
Similar results are obtained using the other
hematological indices (analyses not shown).
The Pb-MTwas unlikely to be positive ifthe
MCV was .70 fl, the Hct was <30%, or the
Hgb was <106 g/l. As with MCH and EP,
these factors identify overlapping, but not
identical, groups of children with very low
likelihood ofhaving positive Pb-MTs. Thus,
having a low (below cutoff) value on any of
these measures (EP, MCH, MCV, Hgb,
Hct) was associated with a low uPbr (<0.6).
BPb, age, EP, and MCH weresignificant-
ly correlated with uPbr in bivariate analyses
(Table 3). To determine whether these four
correlates of uPbr accounted independently
for part ofthe variance in uPbr, we evaluated
a series of multiple regression models that
included these variables, as well as MCV,
Hgb, and HCT (forward stepwise regression).
We found that onlyage, BPb, EP, and MCH
significantly contributed to the models with-
out interactions (Table 3). Together they
accounted for30% ofthevariance in uPbr.
Because red cell indices are lower in
African-American than in other American
children and 45% of the children in this
group were African-American, we examined
the effect ofrace on Pb-MT outcomes (15).
There were no significant differences in the
percentage of children with high or low
indices. The percentage ofpositive Pb-MTs
were 27% and 24% in the African-
American and non-African-American
(mainly Hispanic) children, respectively
(p>0.05 by chi-square test).
Discussion
Just under 1% ofthe children screened for
Pb poisoning in the catchment area ofour
medical center during the early 1990s (pri-
marily the Bronx and lower Westchester
counties) have BPb levels .1.21 pmol/l (25
pg/dl). An additional 8% have BPb levels
between 0.48 and 1.21 pmol/l (10-25
pg/dl). Our Pb clinic patients have the
characteristics of a population most at risk
for childhood Pb poisoning: it is composed
primarily of minority (Hispanic and
African-American) children who live in the
inner city, have a low income level, and live
in housing built before 1960 (16).
Clinical interventions for these children
should include identification and eradication
Table 1. Results by erythrocyte protoporphyrin (EP)
category
Variable
Age (years)
BPbb(pg/dl)
uPbr
Hgb (g/l)
Hct %)
MCV(fl)
MCH (pg)
(+) Pb-MT[n(%)]
EP<35 pg/d1a
(n= 21)
3.4 ± 1.2
31 ± 4
0.31 ± 0.13
121 ± 11
36 ± 3
74 ± 8
25 ± 3
1(5%)
EP235 pg/dl1
(n= 101)
3.4± 1.5
32 ± 6
0.49 ± 0.26*
120 ± 11
35 ± 3
75±7
26 ± 3
28 (28%)*
Abbreviations: BPb, blood lead; uPbr, urinary lead
to CaNa2EDTA dose ratio; Hgb, hemoglobin; Hct,
hematocrit; MCV, mean corpuscular volume; MCH,
mean corpuscular hemoglogin; Pb-MT, lead mobi-
lization test. Values are given as mean ± standard
deviation exceptfor Pb-MT.
aTo convertto pmol/l, multiply by 0.0177.
bTo convertto pmol/l, multiply by0.0483.
*p<0.05; between group comparisons by t-test or
chi-square.
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of the environmental Pb source, nutritional
information and supplementation with
essential minerals (as indicated), and the
possibility of chelation. Selection for chela-
tion therapy has been based on provider
preference (17). Those who believe that
moderately elevated BPb levels are highly
associated with the risk ofneurotoxicity and
therefore should be reduced promptly offer
chelation in the hope that it will be success-
ful at removing Pb expeditiously.
Historically, chelation with parenterally
administered medications was provided in
the hospital. Chelation may have become
more acceptable to some providers with the
availability of the orally administered drug
dimercaptosuccinic acid (succimer). This
drug is at least as capable as CaNa2EDTA at
lowering BPb levels over 5-day treatment
periods when comparable dosage is adminis-
tered, determined on a per meter squared
basis (succimer at 1,050 mg/m2/day, not at
30 mg/kg/day as recommended by the drug
company in its inserts, because the recom-
mended dose results in undertreatment in
children; the larger succimer dose is compa-
rable to CaNa2EDTA at 1,000 mg/m2/day)
(18,19). However, a rebound in BPb levels
occurs after cessation of treatment with
either drug. In addition, transient toxicities
have occurred during succimer use, and the
drug increases intestinal Pb absorption in
normal humans (20). Other providers, cit-
ing the lack of controlled studies that
1.6
1.4
1.2
a.
=2 0.8
demonstrate either a sustained effect of
chelation therapy in asymptomatic, moder-
ately Pb-poisoned children on BPb levels or
neurobehavioral outcomes, have refrained
from offering anydrug treatment.
In this study, we postulated that EP lev-
els, as a marker ofPb toxicity that lags weeks
behind the increase in BPb levels after inges-
tion, may help identify children for chela-
tion therapy. Children with high EP levels
due to Pb poisoningwould excrete more Pb;
children with low EP levels, indicating a
smaller body burden of Pb or recent expo-
sure, would excrete less Pb. Our results sup-
port these hypotheses: children with low EP
values were unlikely to excrete significant
amounts of Pb when given a test dose of a
chelating agent. In contrast, children with
high EP levels were much more likely to
excrete large amounts ofPb.
Because an elevated EP level may be due
to iron deficiency as well as to Pb poison-
ing, we then examined red cell indices
obtained prior to the Pb-MT as indirect
measures ofiron status (21). We found that
low MCH, MCV, or Hgb levels, which are
consistent with but not diagnostic of Fe
0.6
0.4
0.2
25 35 50 75 100 125 150 175 200 225 250
EPKig/dl
1.6
1.4
1.2
. 0.8
0.6
0.4
0.2
Table 2. Lead mobilization test (Pb-MT) results by
erthrocyte protoporphyrin (EP) and mean corpus-
cular hemoglobin (MCH)
Total Pb-MT(-) Pb-MT(+)
EP(pg/dl)a MCH (pg) (n) (n) (n)
<35 <23 4 4 0
.23 17 16 1
.35 <23 14 14 0
.23 87 59 28*
aTo convertto pmol/l, multiply by0.0177.
*p<0.05 between group comparisons for EP>35
versus EP.35 pg/dl and for MCH<23 versus MCH
223 pg.
Table 3. Correlations with urinary Pb to CaNa2EDTA
dose ratio
Bivariate Multivariate
Correlation Standardized
Variable coefficient p-value coefficient p-value
Age 0.336 0.000 0.332 0.000
BPb 0.236 0.009 0.191 0.020
EP 0.343 0.000 0.332 0.000
MCH 0.234 0.009 0.157 0.054
MCV 0.153 0.092
Hct -0.091 0.321
Hgb 0.045 0.623
13 15 17 19 21 23 25
MCH pg
Figure 1. (A) The relationship between erythrocyte protoporphy
results expressed as uPbr. The vertical bar at 35 pg/dl indicate
level; the horizontal bar at 0.6 represents the cutoffforthe Pb-M
= 0.75; and EP = 424, uPbr = 0.74. (B) The relationship between m
results expressed as uPbr. The bar at 23 pg indicatesthe cutofff
* * ~~~~~Abbreviations: BPb, blood lead; EP, erythrocyte
protoporphyrin; MCH, mean corpuscular hemoglo-
27 29 31 33 35 bin; MCV, mean corpuscular volume; Hct, hemat-
ocrit; Hgb, hemoglobin. The significance levels of
the bivariate correlations are uncorrected for mul-
rin (EP) and lead mobilization test (Pb-MT) tiple tests. The standardized coefficients and p-
ts the current definition for an elevated EP values of the significant variables in the final mul-
T. Two cases are notshown: EP= 299, uPbr tivariate model derived from forward stepwise
lean corpuscular volume (MCH) and Pb-MT regression analyses are shown in the columns on
or MCH that best predicts the Pb-MT. the right.
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deficiency, were associated with low urinary
Pb excretion. This supports our second
hypothesis, namely, that a subset of chil-
dren with both elevated BPb and EP levels
and biochemical evidence consistent with
Fe deficiency will excrete less Pb. In this
regard, we have reported previously that
children with low ferritin levels excreted less
Pb during the Pb-MT, despite comparable
BPb levels at the time oftesting (22). These
hematologic measures are not independent
predictors of uPbr, as shown in the regres-
sion analyses, and measurement of MCH
should suffice for the purpose ofpredicting
Pb-MT outcomes. We did not determine in
this study whether the failure to induce a
Pb diuresis in these children was due to
lower body stores ofPb, a lack ofefficacy of
drug in the presence of Fe deficiency, or
that low CBC indices per se affect or reflect
Pb availability to a chelating agent indepen-
dent ofFe deficiency.
In this group, age was independently
and positively related to uPbr. We speculate
that age was a surrogate for duration ofPb
exposure prior to enrollment at the clinic.
Stratifying by BPb and then by EP did
not markedly improve predictability of
uPbr. For example, although 100% of our
children with BPb .1.94 limol/l (40 pg/dl)
had elevated EP levels, only 47% were Pb-
MT positive. Thus, BPb by itselfwas not a
good predictor ofuPbr in this limited BPb
range. This is consistent with our previous
studies (10). The high percentage ofelevat-
ed EP levels in this study group probably
reflects the period oftransition from its use
as the screening tool of choice to direct
BPb measurements.
Moderately elevated BPb levels indicate
absorption ofPb, but do not necessarily pre-
dict the total amount ofPb accumulated in
the body, the susceptibility ofthe individual
child to a given amount ofPb, or the ability
ofchelating agents to enhance Pb excretion
(22-24). Other diagnostic methods such as
bone Pb measurements by X-ray fluores-
cence (XRF), EP level determinations, and
the Pb-MT address some of these issues
more directly (6,25,26). The XRF tech-
niques, L-XRF and K-XRF, are noninvasive
methods for measuring cortical (L-XRF)
and trabecular (K-XRF) bone Pb content.
L-XRF methodology has been used exten-
sively in young children (8,25,26); compari-
son of bone Pb measurements and Pb-MT
results in children with BPb levels between
1.21 and 2.66 pmol/l (25-55 pg/dl) yielded
a correlation coefficient of0.472 (p<0.001),
which was somewhat less than the correla-
tion between BPb and Pb-MT of 0.701 in
the same children (25). At present, XRF
methodologies are available only at a few
research centers nationally. In general, the
Pb-MT is a difficult test to perform in very
young children in other than expert settings.
In contrast, the EP test is readily available
from commercial laboratories and can be
obtained from the same blood sample drawn
for BPb determination. Ultimately, selection
of children for chelation therapy should be
based on the results of randomized con-
trolled studies showing efficacy ofchelation
at removing Pb and improving measures of
Pb-induced toxicity, or at least the cessation
of further toxic events. These studies have
yet to be completed in children with moder-
atelyelevated BPb levels.
The Pb-MT has become a controversial
diagnostic tool, with few proponents for its
clinical use (7). Objections to the difficulty
in its execution, its cost, and concern about
redistribution of internal stores of Pb have
diminished its use. In addition, its clinical
relevance is unknown because improve-
ments in neurobehavioral outcomes based
on Pb-MT-determined courses ofchelation
therapy have not been studied to date (27).
Nevertheless, long experience with the
use of the Pb-MT points out a therapeutic
dilemma: groups ofchildrenwith comparable
BPb levels can have significantly different
amounts of Pb in their bodies and different
susceptibility to that Pb which has accumu-
lated. Clearly, those children whose BPb lev-
els are due to recent ingestion without Pb
accumulation or evidence oftoxicity are least
likely to benefit from drug treatment, ifat all.
How do we differentiate these children from
those with longer term exposure, accumula-
tion, and toxicity? Taking an environmental
history mayhelp determine duration ofexpo-
sure, but does not quantify ingestion or body
burden. In contrast, uPbr in response to the
CaNa2EDTA Pb-MT is correlated with bone
Pb levels, and bone is the major reservoir of
Pb (25). Previous work has shown that bone
Pb is mobilized by CaNa2EDTA (26,28,29).
In the current study, the uPbrwas also associ-
atedwith a measure ofPb related toxicity, the
EP level. Thus, children with elevated bone
Pb stores and Pb-related toxicity (high EP
levels) are more likely to excrete greater
amounts of Pb in response to a test dose of
CaNa2EDTA (greateruPbr).
The criteria for interpreting an 8-hr Pb-
MT were derived from a previous 24-hr
version ofthe test in which a full day's dose
of CaNa2EDTA was administered (11).
Furthermore, urinary Pb excretion on the
first day ofa course ofchelation therapy is a
predictor of urinary Pb excretion through-
out the course (18,19). The Pb-MT there-
fore gives some indication of Pb burden
beyond the blood compartment, is associat-
ed with a measure of toxicity, and directly
predicts whether children will excrete Pb at
an enhanced rate in response to drug treat-
ment with CaNa2EDTA and, probably,
succimer. It appears reasonable that chil-
dren who do not excrete much Pb during
the Pb-MT will not excrete much Pb dur-
ing a full course ofchelation; as a corollary,
these children will not have a reduction in
their body burdens of Pb, although they
mayshow a decline in BPb levels.
In this sense, the Pb-MT is a useful tool
for differentiating groups of children with
moderately elevated BPb levels as to their
expected responsiveness to chelation-
induced Pb excretion. What it does not pro-
vide at the present time, even in children
who are large Pb excreters, is a prediction of
clinical outcomes, such as improvement in
cognitive test scores after chelation therapy
(27). Unfortunately, there are no publica-
tions of studies that have used randomized
controlled designs to test chelation efficacy
for children with moderately elevated BPb
levels (with or without the Pb-MT), iflong-
term outcomes on cognitive measures are
used as the gold standard.
In summary, in children with moder-
ately elevated BPb levels, the EP and CBC
indices are particularly useful adjuncts in
predicting responsiveness to the chelating
agent CaNa2EDTA. This observation can
probably be extended to treatment with
succimer because children with comparably
elevated BPb levels excrete similar amounts
of Pb daily, whether treated with
CaNa2EDTA or appropriate doses of suc-
cimer (18,19). Children with either an EP
<0.62 pmol/l (<35 pg/dl), an MCH <23
pg, an MCV <70 fl, or an Hgb <106 g/l
are very unlikely to respond to drug treat-
ment with Pb diuresis. We do not recom-
mend chelation therapy in such children
until future studies demonstrate clinical
efficacy. Fe therapy should be initiated for
those with indices consistent with Fe defi-
ciency. Because most Pb-poisoned children
with elevated EP levels and CBC indices
above the thresholds defined in this paper
still have negative Pb-MT results, further
diagnostic evaluation appears to be war-
ranted prior to the initiation of chelation
therapy. These evaluations may include the
Pb-MT, bone Pb measurement, or repeat-
edly elevated blood Pb and EP analyses.
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